POLA-Hi-CHP+orelabrutinib

Phase 2

POLA-Hi-CHP+orelabrutinib is one of 4 therapeutic programs targeting DLBCL - Diffuse Large B Cell Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

DLBCL - Diffuse Large B Cell LymphomaNot yet recruiting

DLBCL - Diffuse Large B Cell LymphomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

10 competitors in DLBCL - Diffuse Large B Cell Lymphoma

#DrugCompanyPhaseTrials

R-CHOP

IIncyte Biosciences Japan GK

Phase 2

1 2

R-Minichop

UUniversität des Saarlandes

Phase 2

1 3

POLA-R-CHP

FFudan University

Phase 2

1 4

POLA-Hi-CHP+orelabrutinib

OOu Bai, MD/PHD

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 2Not yet recruiting

DLBCL - Diffuse Large B Cell Lymphoma

NCT07677813

Clinical

Trials by Indication[1]

DLBCL - Diffuse Large B Cell Lymphoma1 trial

Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study

Not yet recruiting·OOu Bai, MD/PHD·Phase 2·NCT07677813·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for POLA-Hi-CHP+orelabrutinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for POLA-Hi-CHP+orelabrutinib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ou Bai, MD/PHD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: OOu Bai, MD/PHD

POLA-Hi-CHP+orelabrutinib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

DLBCL - Diffuse Large B Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News